Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia - Trial NCT05309213
Access comprehensive clinical trial information for NCT05309213 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Beijing Immunochina Medical Science & Technology Co., Ltd. and is currently Not yet recruiting. The study focuses on Leukemia. Target enrollment is 58 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Beijing Immunochina Medical Science & Technology Co., Ltd.
Timeline & Enrollment
Phase 1/2
Apr 01, 2022
Jun 01, 2025
Primary Outcome
Incidence of Treatment Related adverse events (AEs),Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood and bone marrow)
Summary
This is a phase I/II, open-label, multicenter study to assess the efficacy and safety of IM19
 CAR-T cells in R/R B-cell Acute Lymphoblastic Leukemia
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05309213
Non-Device Trial